Osprey Medical is a medical device company focused on the development and commercialisation of products that are designed to reduce the incidence of contrast induced nephropathy (CIN). We are a US based company with strong roots in Australia. Our core technology was developed at the Baker Heart and Diabetes Institute in Melbourne, Australia.
Osprey Medical's CINCOR™ System is designed to remove dye (contrast) from the heart before it can enter the kidneys and cause damage known as contrast induced nephropathy (CIN). Dye is routinely used to x-ray the heart during angioplasty and stenting procedures. Patients at high risk of CIN often have pre-existing chronic kidney disease. Prevention of CIN in high risk patients may lead to shorter hospital stays, improved patient outcomes, and may ultimately save patients' lives.
Osprey Medical’s Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers acquisitions. Osprey Medical’s advisory board comprises world-recognised experts in heart and kidney disease.
Main business focus/
Listing by sector:
- Medical Devices - Medical device manufacturer
|Contact person||Mike McCormick|
|Job Title||President & CEO|
|Address||7600 Executive Drive|
|City/Suburb||Eden Prairie, Minnesota, USA|